New vaginal suppository aims to clear HPV and prevent cervical cancer
NCT ID NCT07572396
First seen May 11, 2026 · Last updated May 16, 2026 · Updated 1 time
Summary
This study tests an experimental vaginal suppository called Dysplasix in women with high-risk HPV and mild cervical cell changes (ASC-US or LSIL). The goal is to see if the treatment can clear the virus and reverse the abnormal cells. Forty-five women will receive either the active suppository or a placebo over 19 days, and be followed for two months. The study also monitors safety and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Prince of Wales Hospital
RECRUITINGShatin, New Territories, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.